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ABSTRACT
This study investigated the histo-morphological effect(s) of Zidovudine therapy on the kidney of
Wister rats. Fifteen Wistar rats obtained from the Animal house of the College of Medicine, 
Ambrose Alli University, Ekpoma, Edo State, Nigeria, were used for this study. A three week 
period of acclimatisation was allowed. They were subsequently weighed and randomly stratified 
into a control (A; n=5) and two treatment groups - B (low dose; n=5) and C (high dose; n=5). 
Groups B and C received varied doses of Zidovudine (6mg/kg and 12mg/kg respectively). After 
the completion of a 21 day treatment exercise, renal tissues were harvested from each of the 
groups and taken for histo-morphologic analysis The results showed significant body weight 
reduction in the treatment groups as compared to the control  (p<0.05) with mild to moderate 
derangement in the kidney sections of group B (high dose). It can be concluded therefore, that
while low doses of zidovudine can reduce body weight of the animals with no obvious deleterious
effects, higher dose however, has capacity to induce histomorphologic alterations in renal tissues
of rats.
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INTRODUCTION
Pneumocystis carinii is an opportunistic infection (Prekates, et al., 1997) associated with malignant neoplasies like 
Kaposi’s sarcoma (CDC, 1981a; 1981b). The “hydra-headed“ monstrous virus involved is now referred to as the 
Human Immunodeficiency Virus (HIV), which is currently known to be notorious and responsible for the Acquired 
Immunodeficiency Syndrome (AIDS) (UNAIDS, 1998; Ajakaiye, 2002). It has been considered as the worlds 
greatest pandemic ever known to devastate mankind (UNAIDS, 1998) and most prevalent among persons of 
reproductive age; about one third of whom are expectant parents. 
In Nigeria for example, literature has it that an estimated number of 2.95 million of the populace are living with 
HIV/AIDS (Ogundipe, 2009). This huge statistical report has continued to challenge the research community, the 
academia, governments, media organizations, religious groups and several non-governmental organisations the 
world over. A pointer to the veracity of believing this report however, is the “relative porosity” of the routes for the 
spread of this infection. One of the routes by which the infection can spread is in utero, usually referred to as 
mother–to–child transmission (MTCT) (Marinda 2011; Arya 2010) and could involve oral means as breastfeeding 
(Liang 2009), during parturition (child birth) (Arya 2010) and even post-natally (UNAIDS/WHO, 1998; Morgan et 
al., 1990; Adjorlolo-Johnson et al., 1994; Andreasson et al., 1993).
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To help curtail the excesses and devastating menace of this monster called HIV, the WHO in 2000, recommended 
inhibitors of the analogues of the reverse transcriptase enzymes, found in Nucleotides that lack phosphate group 
polymers (Nucleosides), as regimens for people living with HIV/AIDS (Menéndez-Arias, 2002; Clavel and Hance, 
2004). Such Nucleoside analogues include (but not limited to) Zidovudine (Azidothymine--AZT), Didanosine, 
Nevirapine and Lamivudine. Generally, anti-Retrovirals (ARVs) work by inhibiting the enzyme (reverse 
transcriptase) which HIV uses to synthesize a prototype DNA for itself, using the host’s DNA as a template (Gulick 
et al., 1997; Imamichi, 2004).
Although these drugs have been scientifically proven to be efficacious in improving the immunity status of sufferers 
and reducing the viral load to undetectable level as well as elongating the survival of victims (Yazdanpanah 2009),
researchers are however sceptical as to the adverse effect(s) that may be associated with an absolute dependency on 
them by people living with HIV/AIDS. For instance, AZT has been reported to manifest with several side effects, 
with the commonest being Hematological toxicity (severe anaemia and neutropenia), lactic acidosis, nausea, 
vomiting, headache, dizziness, fatigue, insomnia, kidney disorders, weakness and muscle pain at the early weeks of 
its administration (Ministry of Health, Zambia National Formulary Committee, 2008; Sharma 2011). Even though 
polypharmacy (multiple drug administration) plus adjustments in diet will usually tame some of the effects (McCord 
2008; Payer 2010), the toxicity may worsen with time due to tachyphylaxis from the virus (Fisher 2001; Somarriba 
2010; Ahoua 2011REF).
Physiologically, the oral administration of zidovudine usually results in first pass metabolism of the drug in the liver, 
a situation that tends to limit its bioavailability to receptors for therapeutic effect (Thomas et al., 2006; Hurst et al., 
2007; Varma et al., 2010a; Varma et al., 2010b).). Hence, other possible route to bypass the liver has been 
considered as well. Therefore, this study was intends to investigate the effect of zidovudine on the histomorphologic 
architecture of the renal organ. 
MATERIALS AND METHODS
Animals: Fifteen (15) male albino rats, not more than three months of age (each) where obtained from the College 
of Medicine, at Ambrose Alli University (AAU), Ekpoma, Edo State. The reason for restricting their age to 3 
months was because laboratory study of lifespan is currently only feasible for short-lived species, and rats happen to 
show short life expectancy (about 3 years). This signifies that as they age, there’s bound to be a decline in the renal 
clearance of the study drug (zidovudine) due to decline in age and by implication, renal functionality. This 
circumstance usually increases bioavailability and therefore, may thwart the regimen and the therapeutic effect that 
was desired per concentration per body weight of subject (Wister rat). 
Nevertheless, the rats were transported to the animal house of the College of Health Sciences at the Delta State 
University (DELSU), Abraka, Delta State, Nigeria, where they were housed in a wooden cage. They were weighed 
and confirmed to weigh between 180-250g, and thereafter stratified into experimental groups A and B (A = low 
dose; and B = high dose). Group C served as the control. The rats were fed with rat chow from Bendel Foods Ltd 
and allowed to acclimatize for a period of one week after which they were re-weighed. The reason for re-weighing 
the rats was to be sure that the new environment (DELSU environment) had no negative effect on their body initial 
weight, as this will be indicative of a bad acclimatisation process.
Ethical Approval: Ethical consent and approval was granted by the Research and Ethics committee of the College 
of Health Sciences, Delta State University, Abraka, Delta State, Nigeria.
Drugs: Zidovudine (the targeted ARV) was obtained from the anti-retroviral unit of the Central Hospital, Agbor, in 
Delta State. The drugs were analytically graded and administered based on the concentration (in gram/dm3) per unit 
weight (kg equivalence of between 180-250g) of each rat. The reason for the “drug stoichiometry” was to avoid over 
dosage as all drugs are lethal above certain dose. Issues of drug-drug interactions were also put into cognisance. For 
instance, stavudine and doxorubian are known inhibitors of zidovudine. So as a precautionary measure, the rats were 
never given such (both after and before purchases were made).
Drug Administration: The rats (15 in total) were as stated earlier, grouped into three (A, B and C). Experimental 
groups were administered with varying doses of Zidovudine (in water) for a period of 21 days, while group C rats 
received only normal feed and water. Specifically, group A received 6mg/kg (low dose) while group B received 
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12mg/kg (high dose) of Zidovudine. The experimental rats were constantly monitored and their body weight 
changes recorded on weekly basis using an electronic balance. The doses administered to the experimental animals 
were however adjusted to be commensurate with any observed weight gain or loss.  
Sacrifice and Tissue Extraction: 12 hours following the last treatment, the animals (per group) were re-weighed 
and immediately given a cervical dislocation (after anaesthetizing with chloroform). The reason for doing this 12-
hour post drug prandial was to give adequate time for proper drug circulation and metabolism in vivo. Thereafter, 
the pancreas, stomach and kidneys were carefully removed and fixed in a 10% formal-saline for 48 hours. The 
reason for using formal-saline was to keep the tissues at constancy with their ex-vivo environment.
Tissue Processing: With the assistance of a certified anatomist from the Department of Human Anatomy and Cell 
Biology in DELSU, the harvested organs (pancreas, stomach and kidneys) were subjected to standard tissue 
processing techniques that include dehydration, impregnation, embedding, sectioning and staining with 
Haematoxylin and Eosin (H and E) for appropriate microscopy. Photomicrographs were then captured with the aid 
of a 5.0 mega pixel microscope of about 500 resolution capacity, having a serial port for connection with a 
computer’s Universal Serial Board (USB) (see below). 
Statistical Analysis: All the data obtained in this study were expressed as Mean ± SEM (standard error of mean). 
Significant differences were tested using ANOVA with margin of error valued at 0.05. Where p<0.05, results were 
considered statistically significant as appropriate (see below).
RESULTS
On body weight, the results showed a tremendous weight difference in the control group (206.6 ± 92.4)g as 
compared to rats in the experimental groups A (administered low dose) and B (administered high dose), who’s
weights were  1.86±83.18 and 190±84.97 grams respectively. 
Table 1: Comparisons of body weight of control versus low and high dose rats, treated 
with zidovudine




1.2±0.08 3.23 2.31 P < 0.05
High Dose
(Group B)
0.0 ±  0.1 5.0 2.31 P < 0.05
Results are presented in gram, mean ± SD (n = 5).
The results showed a statistically significant reduction in the body weight of the experimental animals as compared 
to the control. In fact, there was a continuous weight loss in the low and high dose groups as shown in the table. 
On renal tissue microscopy, it was observed that the control tissue sections presented intact tissue cytoarchitecture 
with intact cortical glomeruli, tubules and interstitium (Figure 2).  Tissue sections of group A and B treated with low 
and high concentration of Zudovudine, showed moderate interstitial congestion (Figures 3 and 4). 
DISCUSSION
The observed significant reduction in the body weight of the treated rats coincides with the findings from previous 
studies on Zidovudine. Specifically, Lamperth et al. (1991) observed that AZT-treated animals lost 10% of their 
original weight by the end of the 3rd month of the experiment. Similarly, the observed interstitial congestions in the 
treated kidney sections serve as a pointer to the ensuing events at the cellular and molecular levels. This is supported 
by the assertions of Izzedine et al. (2005) and Daugas et al. (2005) that antiretroviral drug can cause renal failure 
through a variety of mechanisms that includes direct renal tubular toxicity (ATN, Fanconi-like syndrome, distal 
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tubular acidosis, obstructions (crystal deposition in the kidney), and glomerular lesions. Indeed, this seeming 
Zidovudine’s capacity to induce renal tissue damage would definitely aggravate HIV’s capacity to induce 
glomerular and vascular or tubule-interstitial nephropathies (Weiner et al., 2003), which are leading cause of end-
stage renal disease (ESRD) especially among black sufferer patients (D’Agati et al., 1998),
Figure 1: A Bar chart showing mean body weights of rats in gram against zidovudin concentration in 
milligrams
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Figure 3: Photomicrograph of rat kidney (H&E x400) treated with low concentration of 
Zudovudine showing moderate interstitial congestion (A).
Figure 4: Photomicrograph of rat kidney (H&E x400) treated with high concentration of Zudovudine for 3 weeks 
showing moderate interstitial congestion A.
A
A
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Undeniably, the tremendous advancements achieved in the management of HIV remains one the great scientific 
feats of the 21st century. Even available reports have shown that mortality rate for HIV-positive individuals have 
declined considerably and continue to do so (Killian 2011; Bhaskaran 2008; Giusti 2011). However, the concerns 
that the indispensability of antiretroviral drugs comes with it a lot of challenges especially a number of troubling 
side effects (Barsoum, 2006) can no longer be ignored. The fact that these drug-induced side effects can diminish 
patients’ quality of life and contribute to an increase the rate of cardiovascular events and diabetes (Escote 2011; 
Tien 2008; Tebas 2008; Palios 2012) is indeed a course for concern.
It is obvious therefore, that Zidovudine has the capacity to induce body weight reduction and histopathological 
alterations in organ systems, with their attendant negative consequences on HIV patients that would surely 
compound the vulnerability status of HIV patients to infections. It is our opinion that there is a need to develop a 
much more efficient chemotherapeutic strategy that would ensure a holistic clinical management of HIV patients, 
especially those that are highly susceptibility to drug induced adverse effects.  
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